Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNCOVER-1: Ixekizumab in Moderate-to-Severe Plaque Psoriasis
NCT01474512Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2011
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of ixekizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started Nov 2011; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01474512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01474512.